Skip to content

Relay Therapeutics

US · RLAY #2273 by market cap Listed 2020
16.12 +0.21 +1.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 15.69 -1.38%
After-hours 16.19 +0.46%
20.7513.4916.122026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RLAY?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +67.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 19.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,971.6% Better than 2%
Net margin -1,800.6% Better than 2%
Return on equity -41.1% Better than 10%
Return on invested capital -42.6% Better than 7%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -17.1% Better than 36%
6-month return 19.1% Better than 82%
12-month return (ex latest month) 168.5% Better than 98%
Distance below 52-week high 24.2% Better than 52%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 22.6x Better than 98%
Debt to assets 5.2% Better than 79%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 79.9% Better than 78%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.89%
1M -12.63%
3M -18.17%
6M +23.81%
YTD +90.54%
1Y +152.66%
3Y +91.90%
5Y -53.26%

Key statistics

Price & volume

Prev close
15.91
Open
15.59
Day range
15.17 - 16.33
Avg price
16.05
Volume
3.98M
Turnover
63.82M
Amplitude
7.26%
52-week range
6.80 - 21.27

Valuation

P/E
-10.01
P/E (TTM)
-10.75
P/B
4.35
EPS
-1.61
Net profit
-355.74M
Net assets
819.10M

Share structure

Market cap
3.56B
Float cap
2.49B
Shares out
220.96M
Float shares
154.74M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-07-16
52-week range 64% of range
6.80 21.27

24.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-26.75M net over the window

Short interest

Shares short
43.63M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Relay Therapeutics (RLAY)?

Relay Therapeutics last traded at 16.12. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Relay Therapeutics's market cap?

About 3.56B.

What is the P/E ratio of Relay Therapeutics?

The trailing twelve-month P/E is -10.75. The Valuation tab shows it against the stock's own five-year range.

Does Relay Therapeutics pay a dividend?

Relay Therapeutics does not currently pay a regular dividend.

Is Relay Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 29.00, which implies 79.9% upside from the current price. This is not investment advice.

What is Relay Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Relay Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Relay Therapeutics discussion 0 comments

Add a comment